Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 79

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 79
---
5,000,000 shares of common stock at a price of $0.80 per share, for aggregate gross proceeds of $4.0 million before deducting the placement agent’s fees and related offering expenses.

21

We have financed our operations primarily through an initial investment from our founder, the issuance and sale of convertible notes, and private and public equity financings. As of September 30, 2025, our cash and cash equivalents were approximately $7.1 million. Based on our balances in cash and cash equivalents as of September 30, 2025, plus net proceeds received under the Company’s ATM Sales Agreement subsequent to September 30, 2025 and October 2025 Registered Direct Offering, we project to have sufficient cash to fund our current operating plan until the end of the first quarter of 2027.

The following table summarizes the net cash provided by (used in) operating activities and financing activities for the periods indicated (in thousands):

Nine Months Ended September 30,20252024Net cash used in operating activities$(6,832)$(12,552)Net cash provided by investing activities— 6,354 Net cash provided by financing activities11,309 424 Net increase (decrease) in cash and cash equivalents$4,477 $(5,774)

Operating Activities

Our cash used in operating activities for the nine months ended September 30, 2025 was $6.8 million, comprising of (i) our net loss of $8.6 million, as adjusted for $1.6 million in non-cash expenses (primarily for non-cash stock based compensation of $1.6 million), and (ii) net changes in operating assets and liabilities of $0.2 million.  

Our cash used in operating activities for the nine months ended September 30, 2024 was $12.6 million, comprising of (i) our net loss of $13.1 million, as adjusted for $2.3 million in non-cash expenses (primarily for non-cash stock based compensation of $2.2 million), and (ii) net changes in operating assets and liabilities of $1.7 million.  

Investing Activities

There were no investing activities during the nine months ended September 30, 2025.

Our cash provided by investing activities during the nine months ended September 30, 2024 was $6.4 million and was due to the redemption of marketable debt securities of $9.4 million,